See more : Infineon Technologies AG (IFX.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Sonova Holding AG (SONVY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sonova Holding AG, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Macquarie Group Limited (MQG.AX) Income Statement Analysis – Financial Results
- OCK Group Berhad (0172.KL) Income Statement Analysis – Financial Results
- Vapotherm, Inc. (VAPO) Income Statement Analysis – Financial Results
- China Oriental Group Company Limited (0581.HK) Income Statement Analysis – Financial Results
- The ODP Corporation (ODP) Income Statement Analysis – Financial Results
Sonova Holding AG (SONVY)
About Sonova Holding AG
Sonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication products; rechargeable hearing aids; wireless headsets, speech enhanced hearables, audiophile headphones, microphones, and wireless transmission systems; and audiological care services. It also provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; consumer hearing products under the Sennheiser brand; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton brands. The company sells its products through independent distributors; and provides hearing care services through a network of approximately 3,600 stores and clinics. It operates in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.63B | 3.74B | 3.36B | 2.60B | 2.92B | 2.76B | 2.65B | 2.40B | 2.07B | 2.04B | 1.95B | 1.80B | 1.62B | 1.62B | 1.50B | 1.25B | 1.20B | 1.07B | 866.68M | 660.38M | 637.60M | 550.54M | 576.08M |
| Cost of Revenue | 1.01B | 1.15B | 943.20M | 764.20M | 877.70M | 843.40M | 827.22M | 783.22M | 723.66M | 647.56M | 610.86M | 555.48M | 513.92M | 498.02M | 441.71M | 381.98M | 363.20M | 340.72M | 289.10M | 242.56M | 269.94M | 271.44M | 280.25M |
| Gross Profit | 2.62B | 2.59B | 2.42B | 1.84B | 2.04B | 1.92B | 1.82B | 1.61B | 1.35B | 1.39B | 1.34B | 1.24B | 1.11B | 1.12B | 1.06B | 867.22M | 841.58M | 732.08M | 577.59M | 417.81M | 367.67M | 279.11M | 295.83M |
| Gross Profit Ratio | 72.28% | 69.28% | 71.96% | 70.63% | 69.91% | 69.48% | 68.74% | 67.31% | 65.07% | 68.18% | 68.69% | 69.06% | 68.27% | 69.20% | 70.56% | 69.42% | 69.85% | 68.24% | 66.64% | 63.27% | 57.66% | 50.70% | 51.35% |
| Research & Development | 261.00M | 242.80M | 229.30M | 203.20M | 166.10M | 148.40M | 142.90M | 132.03M | 125.86M | 130.90M | 125.66M | 113.88M | 116.18M | 107.76M | 87.03M | 77.38M | 76.45M | 67.59M | 62.78M | 48.93M | 58.20M | 48.88M | 31.45M |
| General & Administrative | 340.90M | 330.20M | 320.90M | 250.90M | 309.00M | 269.30M | 265.50M | 242.89M | 194.22M | 201.04M | 195.23M | 181.52M | 168.67M | 185.19M | 141.97M | 117.72M | 115.00M | 108.10M | -112.74M | -73.35M | 78.22M | 60.87M | 70.10M |
| Selling & Marketing | 1.33B | 1.32B | 1.10B | 881.20M | 1.03B | 1.02B | 934.50M | 815.02M | 638.24M | 613.22M | 589.63M | 559.08M | 503.35M | 498.59M | 402.63M | 340.31M | 309.20M | 278.98M | 205.73M | 159.12M | 126.14M | 116.24M | 124.41M |
| SG&A | 1.68B | 1.59B | 1.41B | 1.08B | 1.34B | 1.24B | 1.20B | 1.01B | 807.67M | 814.26M | 784.85M | 740.59M | 672.02M | 683.78M | 544.59M | 458.03M | 424.20M | 387.08M | 92.99M | 85.77M | 204.36M | 177.12M | 194.51M |
| Other Expenses | 14.70M | 0.00 | 0.00 | 0.00 | -23.40M | 4.10M | -1.80M | -1.26M | -18.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.28M | 268.00K | -304.00K | -280.00K | 0.00 | 0.00 |
| Operating Expenses | 1.95B | 1.83B | 1.64B | 1.28B | 1.53B | 1.38B | 1.34B | 1.15B | 951.54M | 958.45M | 936.42M | 1.08B | 810.82M | 812.37M | 650.62M | 542.20M | 514.84M | 6.23M | 356.17M | 297.98M | 272.95M | 316.47M | 236.06M |
| Cost & Expenses | 2.96B | 2.98B | 2.58B | 2.04B | 2.41B | 2.23B | 2.17B | 1.93B | 1.68B | 1.61B | 1.55B | 1.64B | 1.32B | 1.31B | 1.09B | 924.18M | 878.04M | 346.96M | 645.26M | 540.54M | 542.89M | 587.90M | 516.31M |
| Interest Income | 1.20M | 1.50M | 1.40M | 1.80M | 2.50M | 1.60M | 1.62M | 3.80M | 2.01M | 1.07M | 2.13M | 2.61M | 4.42M | 0.00 | 5.05M | 8.17M | 11.33M | 9.04M | 4.37M | 1.19M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 28.20M | 23.10M | 34.50M | 24.00M | 8.80M | 5.10M | 9.36M | 13.60M | 12.25M | 2.95M | 7.64M | 5.92M | 5.98M | 0.00 | 9.10M | 8.35M | 33.13M | 3.46M | 1.01M | 3.18M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 246.20M | 239.70M | 211.10M | 196.10M | 200.10M | 127.60M | 134.76M | 111.84M | 88.74M | 84.95M | 83.10M | 81.66M | 78.31M | 102.85M | 208.17M | 40.75M | 35.25M | 32.15M | 27.00M | 25.31M | 32.27K | 874.69K | 32.05K |
| EBITDA | 921.70M | 978.70M | 960.90M | 755.30M | 711.00M | 659.60M | 615.50M | 566.46M | 487.28M | 508.23M | 485.32M | 236.04M | 366.07M | 409.16M | 616.15M | 371.86M | 371.68M | 319.82M | 244.85M | 153.61M | 94.75M | -36.48M | 59.80M |
| EBITDA Ratio | 25.41% | 26.79% | 29.61% | 29.03% | 24.38% | 24.03% | 23.03% | 24.05% | 23.43% | 24.97% | 24.87% | 13.15% | 23.06% | 27.50% | 51.50% | 29.77% | 30.85% | 29.81% | 28.12% | 23.38% | 14.86% | -6.63% | 10.38% |
| Operating Income | 669.90M | 761.80M | 785.10M | 559.20M | 510.90M | 536.40M | 474.49M | 464.25M | 396.74M | 429.07M | 404.03M | 155.56M | 287.70M | 270.81M | 406.75M | 325.01M | 326.74M | 287.67M | 212.70M | 125.80M | 94.71M | -37.36M | 59.77M |
| Operating Income Ratio | 18.47% | 20.38% | 23.34% | 21.49% | 17.52% | 19.41% | 17.93% | 19.38% | 19.15% | 21.08% | 20.71% | 8.66% | 17.76% | 16.75% | 27.11% | 26.02% | 27.12% | 26.81% | 24.54% | 19.05% | 14.85% | -6.79% | 10.38% |
| Total Other Income/Expenses | -22.60M | -31.10M | -31.80M | -19.00M | -7.60M | -6.60M | -7.26M | -6.35M | -6.38M | -8.75M | -9.45M | -211.21M | -5.92M | -10.70M | -160.30M | -2.26M | -23.44M | -441.64M | 4.13M | -673.00K | -975.00K | -4.48M | -6.62M |
| Income Before Tax | 647.30M | 711.70M | 725.20M | 598.50M | 500.00M | 527.50M | 475.74M | 417.47M | 395.49M | 420.32M | 394.58M | 148.46M | 281.78M | 260.11M | 246.46M | 322.76M | 303.30M | 284.21M | 216.83M | 125.12M | 93.74M | -41.84M | 53.15M |
| Income Before Tax Ratio | 17.85% | 19.04% | 21.56% | 23.00% | 17.14% | 19.09% | 17.98% | 17.43% | 19.09% | 20.65% | 20.22% | 8.27% | 17.40% | 16.09% | 16.43% | 25.84% | 25.17% | 26.49% | 25.02% | 18.95% | 14.70% | -7.60% | 9.23% |
| Income Tax Expense | 37.80M | 57.30M | 64.60M | 15.10M | 12.90M | 69.40M | 71.51M | 61.15M | 51.21M | 52.00M | 47.20M | 37.59M | 35.37M | 29.03M | 29.83M | 38.65M | 29.16M | 41.33M | 43.33M | 29.27M | 24.38M | 4.95M | 10.41M |
| Net Income | 601.00M | 647.50M | 649.00M | 581.00M | 483.20M | 454.10M | 400.10M | 349.17M | 337.03M | 359.99M | 340.83M | 109.75M | 246.76M | 231.01M | 217.22M | 284.82M | 273.35M | 241.63M | 172.47M | 95.02M | 68.88M | -46.88M | 42.63M |
| Net Income Ratio | 16.57% | 17.32% | 19.29% | 22.33% | 16.57% | 16.43% | 15.12% | 14.58% | 16.27% | 17.69% | 17.47% | 6.11% | 15.23% | 14.29% | 14.48% | 22.80% | 22.69% | 22.52% | 19.90% | 14.39% | 10.80% | -8.51% | 7.40% |
| EPS | 10.05 | 10.75 | 10.42 | 9.23 | 7.56 | 6.93 | 6.08 | 5.31 | 5.08 | 1.07 | 1.01 | 0.33 | 0.74 | 0.70 | 0.66 | 0.86 | 0.81 | 0.72 | 0.52 | 0.29 | 0.21 | -0.14 | 0.26 |
| EPS Diluted | 10.05 | 10.71 | 10.35 | 9.19 | 7.52 | 6.90 | 6.06 | 5.30 | 5.07 | 1.06 | 1.01 | 0.33 | 0.74 | 0.69 | 0.65 | 0.86 | 0.80 | 0.71 | 0.51 | 0.28 | 0.21 | -0.14 | 0.26 |
| Weighted Avg Shares Out | 59.80M | 60.22M | 62.27M | 62.97M | 63.94M | 65.50M | 65.75M | 65.76M | 66.39M | 337.56M | 337.88M | 335.53M | 334.63M | 332.50M | 329.66M | 329.71M | 336.66M | 334.35M | 333.02M | 329.93M | 328.16M | 327.48M | 163.11M |
| Weighted Avg Shares Out (Dil) | 59.79M | 60.43M | 62.71M | 63.22M | 64.29M | 65.77M | 65.97M | 65.85M | 66.49M | 338.44M | 338.38M | 336.17M | 335.19M | 335.27M | 333.09M | 331.05M | 340.23M | 338.79M | 336.01M | 333.53M | 330.22M | 328.60M | 163.60M |
Sonova Holding AG (SONVF) Q2 2025 Earnings Call Transcript
Sonova Holding AG (OTCPK:SONVF) Q2 2025 Earnings Conference Call November 19, 2024 7:00 AM ET Company Participants Arnd Kaldowski - CEO Birgit Conix - CFO Thomas Bernhardsgrutter - Senior Director, IR Conference Call Participants Hassan Al-Wakeel - Barclays Julien Ouaddour...
GMED or SONVY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks?
Swiss hearing aid maker Sonova resumes supplying Costco, source says
Swiss hearing aid maker Sonova is resuming supplies to Costco , a source with knowledge of the matter told Reuters on Monday.
GMED or SONVY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks?
HOLX or SONVY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
GMED vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
TFX vs. SONVY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Instruments stocks have likely encountered both Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks presents investors with the better value opportunity right now?
HOLX vs. SONVY: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
HOLX vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
HOLX or SONVY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or SONOVA HOLDING (SONVY). But which of these two companies is the best option for those looking for undervalued stocks?
Source: https://incomestatements.info
Category: Stock Reports